Related references
Note: Only part of the references are listed.2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews
Paula Byrne et al.
BMJ OPEN (2019)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Medicalisation, risk and the use of statins for primary prevention of cardiovascular disease: a scoping review of the literature
Paula Byrne et al.
HEALTH RISK & SOCIETY (2019)
Statin wars: have we been misled about the evidence? A narrative review
Maryanne Demasi
BRITISH JOURNAL OF SPORTS MEDICINE (2018)
Methodological Standards for Meta-Analyses and Qualitative Systematic Reviews of Cardiac Prevention and Treatment Studies A Scientific Statement From the American Heart Association
Goutham Rao et al.
CIRCULATION (2017)
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis
Michael G. Silverman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Interpretation of the evidence for the efficacy and safety of statin therapy
Rory Collins et al.
LANCET (2016)
How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease
David M. Diamond et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2015)
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Neil J. Stone et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Statin Therapy for Primary Prevention of Cardiovascular Disease
Fiona C. Taylor et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Everyone under statin?
Helene Vaillant-Roussel et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2012)
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
B. Mihaylova et al.
LANCET (2012)
Statin myopathy: A common dilemma not reflected in clinical trials
G. FERNANDEZ et al.
CLEVELAND CLINIC JOURNAL OF MEDICINE (2011)
GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Statins and All-Cause Mortality in High-Risk Primary Prevention A Meta-analysis of 11 Randomized Controlled Trials Involving 65 229 Participants
Kausik K. Ray et al.
ARCHIVES OF INTERNAL MEDICINE (2010)
Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women From Primary Prevention Trials
Samia Mora et al.
CIRCULATION (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review
Gloria Cordoba et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Cholesterol screening and the Gold Effect
Alison Hann et al.
HEALTH RISK & SOCIETY (2010)
How Numeracy Influences Risk Comprehension and Medical Decision Making
Valerie F. Reyna et al.
PSYCHOLOGICAL BULLETIN (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Prevalence of musculoskeletal pain and statin use
Catherine Buettner et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Statistical illiteracy undermines informed shared decision making
Wolfgang Gaissmaier et al.
ZEITSCHRIFT FUR EVIDENZ FORTBILDUNG UND QUALITAET IM GESUNDHEITSWESEN (2008)
Efficacy and safe of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes - The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)
Robert H. Knopp et al.
DIABETES CARE (2006)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
C Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
HM Colhoun et al.
LANCET (2004)
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):: a multicentre randomised controlled trial
PS Sever et al.
LANCET (2003)
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
JI Cleeman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
